Cite
HARVARD Citation
Ricciuti, G. et al. (2018). Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study. Hematological oncology. 36 (1), pp. 44-48. [Online].